A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z

Recent news on Urso 250


Axcan Pharma Continues Solid Growth in Fiscal 2007, With Record ...  -  May 10, 2007
CCNMatthews (press release),The names CANASA, CARAFATE, DELURSAN, LACTEOL, PANZYTRAT, PYLERA, SALOFALK, ULTRASE, URSO, URSO DS, URSO 250, URSO FORTE and VIOKASE appearing in this press

Strong Start for Axcan Pharma's Fiscal 2007, With Record Revenue ...  -  Feb 8, 2007
Genetic Engineering News (press release),The names CANASA, CARAFATE, DELURSAN, LACTEOL, PANZYTRAT, PYLERA, SALOFALK, ULTRASE, URSO, URSO DS, URSO 250, URSO FORTE and VIOKASE appearing in this press

Axcan Pharma Closes Fiscal 2006 with Record Annual Revenue of ...  -  Nov 30, 2006
Genetic Engineering News (press release),The names CANASA, CARAFATE, DELURSAN, HELIZIDE, ITAX, LACTEOL, PANZYTRAT, PYLERA, SALOFALK, ULTRASE, URSO, URSO DS, URSO 250, URSO FORTE and VIOKASE

Axcan Pharma Closes Fiscal 2006 with Record Annual Revenue of ...  -  Nov 30, 2006
Genetic Engineering News (press release),The names CANASA, CARAFATE, DELURSAN, HELIZIDE, ITAX, LACTEOL, PANZYTRAT, PYLERA, SALOFALK, ULTRASE, URSO, URSO DS, URSO 250, URSO FORTE and VIOKASE

Axcan Announces Strong Third Quarter 2006 Revenue of $76.7 Million ...  Aug 10, 2006
...ursodiol. However, going forward, the Company expects softer sales of URSO 250/URSO FORTE and CANASA in the United States. Regarding ... -Market Wire



Axcan announces record revenue of $72.8 million for the second ...  May 4, 2006
ULTRASE 13.4 21.4 41.8 1.0 2.0 3.0 ----- URSO 250/FORTE/ DS 13.2 29.5 56.5 13.0(2) 15.0(2 ... - Canada NewsWire

Axcan announces record revenue of $72.8 million for the second ...  May 4, 2006
...and VIOKASE for the treatment of certain gastrointestinal symptoms, related to cystic fibrosis in the case of ULTRASE and PANZYTRAT; URSO/URSO 250, URSO FORTE ... - Yahoo! News





Axcan announces record revenue of $70.6 million for the first ...  Feb 9, 2006
...and VIOKASE for the treatment of certain gastrointestinal symptoms, related to cystic fibrosis in the case of ULTRASE and PANZYTRAT; URSO/URSO 250, URSO FORTE ... - Yahoo! News

Axcan announces record revenue of $70.6 million for the first ...  09 Feb 2006
ULTRASE 36.4 14.6% 2.0% ---- URSO 250/FORTE/DS 51.0 6.5% 15.0 ... - PR Newswire


This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional